DataSheet_1_Recognition of Multiple Hybrid Insulin Peptides by a Single Highly Diabetogenic T-Cell Receptor.pdf
The mechanisms underlying the major histocompatibility complex class II (MHCII) type 1 diabetes (T1D) association remain incompletely understood. We have previously shown that thymocytes expressing the highly diabetogenic, I-Ag7-restricted 4.1-T-cell receptor (TCR) are MHCII-promiscuous, and that, in MHCII-heterozygous mice, they sequentially undergo positive and negative selection/Treg deviation by recognizing pro- and anti-diabetogenic MHCII molecules on cortical thymic epithelial cells and medullary hematopoietic antigen-presenting cells (APCs), respectively. Here, we use a novel autoantigen discovery approach to define the antigenic specificity of this TCR in the context of I-Ag7. This was done by screening the ability of random epitope–GS linker–I-Aβg7chain fusion pools to form agonistic peptide–MHCII complexes on the surface of I-Aαd chain-transgenic artificial APCs. Pool deconvolution, I-Ag7-binding register-fixing, TCR contact residue mapping, and alanine scanning mutagenesis resulted in the identification of a 4.1-TCR recognition motif XL(G/A)XEXE(D/E)X that was shared by seven agonistic hybrid insulin peptides (HIPs) resulting from the fusion of several different chromogranin A and/or insulin C fragments, including post-translationally modified variants. These data validate a novel, highly sensitive MHCII-restricted epitope discovery approach for orphan TCRs and suggest thymic selection of autoantigen-promiscuous TCRs as a mechanism for the murine T1D–I-Ag7-association.
History
References
- https://doi.org//10.1016/j.immuni.2010.04.003
- https://doi.org//10.3389/fimmu.2013.00321
- https://doi.org//10.1111/j.0105-2896.2009.00850.x
- https://doi.org//10.1016/j.coi.2011.08.006
- https://doi.org//10.1126/science.aad2791
- https://doi.org//10.1038/329599a0
- https://doi.org//10.1038/nrg1522
- https://doi.org//10.1084/jem.186.10.1663
- https://doi.org//10.2337/diabetes.51.2.325
- https://doi.org//10.1084/jem.186.7.1059
- https://doi.org//10.4049/jimmunol.1300168
- https://doi.org//10.1073/pnas.1211391110
- https://doi.org//10.1038/s41467-019-12902-2
- https://doi.org//10.4049/jimmunol.180.6.3849
- https://doi.org//10.1126/science.284.5418.1351
- https://doi.org//10.1002/ijc.10317
- https://doi.org//10.1038/ni.1844
- https://doi.org//10.1111/j.1365-2567.2010.03362.x
- https://doi.org//10.1034/j.1399-0039.2003.00152.x
- https://doi.org//10.1111/j.0105-2896.2006.00365.x
- https://doi.org//10.1073/pnas.1006545107
- https://doi.org//10.1021/acs.jproteome.8b00875
- https://doi.org//10.1074/jbc.271.44.27475
- https://doi.org//10.1038/s41590-020-0623-7
- https://doi.org//10.1016/j.jaut.2016.10.007
- https://doi.org//10.2337/db19-0620
- https://doi.org//10.2337/db19-0128
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity